News

Karolinska Institutet will use Advaxis immunotherapies to develop allergy treatments using the models that were developed at Karolinska. Advaxis chairman/CEO Thomas Moore said: "The Karolinska Institutet is a

PGen will put in certain know-how and trade secrets including its patented, Elastatropin human based protein, into the collaboration. American CryoStem will contribute certain intellectual property, know-how and

In the multicenter, open-label extension study reported no serious adverse events that were considered drug-related. The most common adverse events that arose during the trial were diarrhea (9.6%),

The randomized, double-blinded, placebo-controlled study met its primary endpoint of a dose-responsive increase in hemoglobin from baseline over the 42 days of the study (p<0.0001). The results show

The filing was based on the Phase III VELOUR study in patients with metastatic colorectal cancer previously treated with an oxaliplatin-containing regimen. The companies have also announced the

Mylan alleges Teva did not keep up valid paragraph IV certifications as a result of its purchase of Cephalon and the FDA should have found Mylan as the

As per the agreement, Zambon will initially invest €20m into Newron, covering the completion of safinamide’s clinical development and the preparation of the application for marketing approval in

The patent is directed to composition and formulations of the XP23829 compound and another patent application directed to therapeutic uses of XP23829 is now pending, the company said.

The Court has ruled that the asserted claims of US patents 7,410,978 , 7,759,359, 7,781,448, 7,781,449 and 7,763,635 for Sanctura XR are invalid. Sanctura XR is indicated for